CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017		Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 16,662		$ 22,088
Available for sale securities	1,511		627
Grants and other accounts receivable	1,420		646
Receivable from affiliates, net (Note 9)	2,278		511
Prepaid expenses and other current assets	1,354		1,777
Total current assets	23,225		25,649
Property, plant and equipment, net	5,423	[1]	5,529
Deposits and other long-term assets	1,005		1,149
Intangible assets, net	7,482	[1]	10,206
TOTAL ASSETS	221,867		142,572
CURRENT LIABILITIES
Accounts payable and accrued liabilities	5,360	[1]	7,144
Capital lease liability, current portion	0		202
Promissory notes, current portion	126		99
Related party convertible debt, net of discount	13		833
Deferred revenues, current portion	513		572
Total current liabilities	6,012		8,850
LONG-TERM LIABILITIES
Deferred revenues, net of current portion	77		308
Deferred rent liabilities, net of current portion	91		50
Lease liability	1,257		1,386
Capital lease liability, net of current and other liabilities	0		310
Related party convertible debt, net of discount	0		1,032
Promissory notes, net of current portion	44		120
Deferred tax liability	4,845		0
Other long-term liabilities	554		8
TOTAL LIABILITIES	12,880		12,064
Commitments and contingencies (Note 13)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of September 30, 2017 and December 31, 2016	0		0
Common shares, no par value, 150,000 shares authorized; 115,804 shares issued and outstanding as of September 30, 2017, and 103,396 shares issued and 102,776 shares outstanding as of December 31, 2016	342,508		317,878
Accumulated other comprehensive income (loss)	141		(738)
Accumulated deficit	(144,363)		(196,321)
Treasury stock at cost: no shares as of September 30, 2017; 620 shares as of December 31, 2016	0		(2,891)
BioTime, Inc. shareholders' equity	198,286		117,928
Noncontrolling interest	10,701		12,580
Total shareholders' equity	208,987		130,508
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	221,867		142,572
OncoCyte Corporation [Member]
CURRENT ASSETS
Equity method investment, at fair value	110,790		0
Asterias Biotherapeutics, Inc. [Member]
CURRENT ASSETS
Equity method investment, at fair value	$ 73,942		$ 100,039

[1] Reflects the effect of the OncoCyte Deconsolidation.